Literature DB >> 9218753

Diabetes results from a late change in the autoimmune response of NOD mice.

L S Gazda1, B Charlton, K J Lafferty.   

Abstract

IDDM in the NOD mouse is the result of a chronic autoimmune process. NOD mice are shown to express benign autoimmunity that converts to a state of malignant autoimmunity and the development of IDDM. Young disease-prone NOD mice are in a state of benign autoimmunity that is correlated with a non-destructive response to islet tissue and the preservation of insulin-containing beta-cells. A proportion of mice with benign autoimmunity convert to having malignant autoimmunity. Clinical diabetes is diagnosed approximately 3 weeks from the development of malignant autoimmunity which is correlated with a destructive response to grafted islet tissue and extensive beta-cell destruction. We conclude that the development of clinical disease is correlated with a change in the state of autoimmunity, that is, from benign to malignant autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218753     DOI: 10.1006/jaut.1997.0138

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

1.  Reversal of established autoimmune diabetes by restoration of endogenous beta cell function.

Authors:  S Ryu; S Kodama; K Ryu; D A Schoenfeld; D L Faustman
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes.

Authors:  Andrew F Ziolkowski; Sarah K Popp; Craig Freeman; Christopher R Parish; Charmaine J Simeonovic
Journal:  J Clin Invest       Date:  2011-12-19       Impact factor: 14.808

3.  Transgenic rescue implicates beta2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice.

Authors:  E E Hamilton-Williams; D V Serreze; B Charlton; E A Johnson; M P Marron; A Mullbacher; R M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

4.  Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes.

Authors:  L Yu; D T Robles; N Abiru; P Kaur; M Rewers; K Kelemen; G S Eisenbarth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

5.  Beta cell MHC class I is a late requirement for diabetes.

Authors:  Emma E Hamilton-Williams; Stephanie E Palmer; Brett Charlton; Robyn M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

6.  The expression of cytokine genes in the peritoneal macrophages and splenic CD4- and CD8-positive lymphocytes of the nonobese diabetic mice.

Authors:  Nik-Soriani Yaacob; Mohd-Arifin Kaderi; Mohd-Nor Norazmi
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

7.  Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models.

Authors:  Helen M McGuire; Stacey Walters; Alexis Vogelzang; Carol M Y Lee; Kylie E Webster; Jonathan Sprent; Daniel Christ; Shane Grey; Cecile King
Journal:  Diabetes       Date:  2011-03       Impact factor: 9.461

8.  Circulating platelet-neutrophil aggregates characterize the development of type 1 diabetes in humans and NOD mice.

Authors:  Sarah K Popp; Federica Vecchio; Debra J Brown; Riho Fukuda; Yuri Suzuki; Yuma Takeda; Rikako Wakamatsu; Mahalakshmi A Sarma; Jessica Garrett; Anna Giovenzana; Emanuele Bosi; Antony Ra Lafferty; Karen J Brown; Elizabeth E Gardiner; Lucy A Coupland; Helen E Thomas; Beng H Chong; Christopher R Parish; Manuela Battaglia; Alessandra Petrelli; Charmaine J Simeonovic
Journal:  JCI Insight       Date:  2022-01-25

9.  Fine mapping of type 1 diabetes regions Idd9.1 and Idd9.2 reveals genetic complexity.

Authors:  Emma E Hamilton-Williams; Daniel B Rainbow; Jocelyn Cheung; Mikkel Christensen; Paul A Lyons; Laurence B Peterson; Charles A Steward; Linda A Sherman; Linda S Wicker
Journal:  Mamm Genome       Date:  2013-08-11       Impact factor: 2.957

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.